Overview

TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study: To explore the comparative effectiveness of BIBF 1120 in terms of : - Progression-free survival (PFS), objective response, overall survival - Evaluate and compare safety

Phase:

Phase 2

Details

Lead Sponsor:

Martin-Luther-Universität Halle-Wittenberg

Collaborators:

GALMED GmbH
GALMED GmbH, Halle, Germany

Treatments:

Fluorouracil
Nintedanib
Oxaliplatin